# Hydra Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hydra-biosciences

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.hydrabiosciences.com
- Total disclosed funding: $78M
- Latest round: Series E (Mar 17, 2015)
- Investors on record: 10

## About

Hydra Biosciences, Inc. is a biotechnology firm dedicated to developing innovative therapeutics leveraging proprietary technology platforms to address unmet medical needs in pain management and rare diseases.Founded in 2001 and headquartered in Cambridge, US, Hydra Biosciences focuses on creating therapeutics targeting various diseases. The company has engaged in five total deals, with its most recent funding round being a Series E in March 2015, raising USD 10.51 mn from Abingworth, Advanced Technology Ventures, BioVentures Investors, and Lilly Ventures. The company's current valuation stands at USD 30.048 mn.Hydra Biosciences specializes in developing and commercializing innovative therapeutics using proprietary technology. Their core offerings include drug candidates aimed at conditions in pain management and rare diseases. These therapeutics interact with specific biological pathways to provide better efficacy and safety than traditional treatments, primarily targeted at North American and European healthcare providers, hospitals, and specialty pharmacies.Hydra Biosciences generates revenue through direct sales of its therapeutics and partnerships with healthcare organizations. Their business model often involves B2B agreements with healthcare providers or distributors, potentially including volume-based pricing or milestone payments linked to the commercialization of flagship products. This strategy enhances market reach and secures a steady revenue stream in the biopharmaceutical sector.Hydra Biosciences plans to utilize the USD 10.51 mn raised in March 2015 to support the development of new products targeting pain management and rare diseases. The company aims to expand into additional markets in North America and Europe by 2025, thereby increasing its footprint in the biopharmaceutical market while addressing unmet medical needs.

## Funding rounds

- Series E, Mar 17, 2015, $11M — Abingworth, Advanced Technology Ventures, BioVentures Investors, Lilly Ventures
- Series D, Jan 16, 2009, $22M — Abingworth, Advanced Technology Ventures, BioVentures Investors, Polaris Partners, Lilly Ventures, MedImmune Ventures, Biogen Idec New Ventures
- Series C, Mar 13, 2008, $17M — Abingworth, Advanced Technology Ventures, BioVentures Investors, New Enterprise Associates, Polaris Partners, Lilly Ventures
- Series B, Jan 12, 2004, $19M — Abingworth, Advanced Technology Ventures, BioVentures Investors, Polaris Partners, Lilly Ventures, Abbott Laboratories, Boston Medical Investors
- Series A, Jul 25, 2002, $10M — Abingworth, Advanced Technology Ventures, New Enterprise Associates, Polaris Partners, Boston Medical Investors

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B, Series C, Series D, Series E
- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series A, Series B, Series C, Series D, Series E
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series C
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C, Series D
- Boston Medical Investors (https://capitalatlas.ai/funds/boston-medical-investors) — Series A, Series B
- BioVentures Investors (https://capitalatlas.ai/funds/bioventures-investors) — Series B, Series C, Series D, Series E
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series B, Series C, Series D, Series E
- Abbott Laboratories — Series B
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series D
- Biogen Idec New Ventures (https://capitalatlas.ai/funds/biogen-idec-new-ventures) — Series D